COVID-19 In the Pipeline Therapeutics

Released On
June 21, 2021

Expires On
June 21, 2022

Media Type

Completion Time
60 minutes

Cardiology, Critical Care, Emergency Medicine, Geriatric Medicine, Infectious Disease, Pediatrics, Primary Care, Pulmonology

Infectious Disease, COVID-19

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine, DKBMed and the Institute for Johns Hopkins Nursing.

This activity is supported by independent educational grants from Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., and Eli Lilly and Company.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours
  • Physician Assistants - maximum of 1.0 AAPA credits

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for health care providers in the care of patients with COVID-19.

Program Overview

In this on-demand video webinar, Dr. Paul Auwaerter discusses potential COVID-19 treatments currently in the pipeline.

  • Outpatient treatments: inhaled remdesivir, oral antivirals, inhaled budesonide, and monoclonal antibodies
  • Inpatient treatments: lenzilumab, baricitinib, and dexamethasone
  • Clinical progression, risk factors, and home care for COVID-19 patients

Learning Objectives

After completing this activity, the participant should be better able to:

  • Appraise the efficacy, safety and indications for treatments for patients with COVID requiring hospitalization.
  • Evaluate management strategies for outpatients with mild to moderate COVID-19.
  • Explain mechanisms of action of monoclonal antibodies (mAbs) and other current and in-development treatments for COVID-19.
  • Describe best practices for managing patients with COVID-19 with mAbs and other agents.



Paul G Auwaerter, MD, MBA, FIDSA

Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Clinical Director, Division of Infectious Diseases
Johns Hopkins University School of Medicine

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Designation Statement – Enduring Materials

The Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until June 10, 2022. PAs should only claim credit commensurate with the extent of their participation..

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Credit Designation

This 1.0 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity June 11, 2022.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

It is the policy of the Institute for Johns Hopkins Nursing that the presenter and provider globally disclose conflicts of interest. The IJHN has established policies that will identify and resolve conflicts of interest prior to this educational activity.

Faculty / Presenter Reported Financial Relationship

Paul G. Auwaerter, MD, MBA, FIDSA

  • Ownership Equity: JNJ
  • Scientific Consulting: Verily, EMD Serono
  • DMSB: Humanigen

Planners and Managers

The PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose. The IJHN Nurse Planner has nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 11, 2021 through June 10, 2022, participants must read the learning objectives and faculty disclosures and study the educational activity. In order to receive nursing contact hours, participants must also complete and submit an evaluation.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the IJHN name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.